In vivo 13 C magnetic resonance spectroscopy (MRS) enables the investigation of cerebral metabolic compartmentation while, e.g. infusing
Introduction
13 C magnetic resonance spectroscopy (MRS) is a powerful tool that enables direct measurement of brain metabolic fluxes in vivo in humans and in animal models. The low natural abundance of the 13 C isotope (1.1%) has been exploited by infusing 13 C-labeled substrates, used as tracers, to explore the metabolic fate of the substrate through metabolic pathways of interest by measuring the progressive labeling of the downstream metabolic products. Specifically, given the central role of glucose (Glc) in brain energetics, [1- 13 C]glucose and [1,6-13 C 2 ]glucose have been used to assess brain metabolism and neurotransmission mainly through the measurement of the progressive enrichment of glutamate (Glu) and glutamine (Gln) in the positions C4, C3, and C2. [1] [2] [3] From the separate detection of Glu and Gln 13 C peaks, it is possible to assess the rate of the tricarboxylic acid (TCA) cycle, the pyruvate carboxylase pathway (PC), the Glu and Gln cycle through neurotransmission, and the exchange between 2-oxoglutarate (OG) and Glu.
Alternatively, brain glucose metabolism can be measured with 18 F-fluorodeoxyglucose positron emission tomography ( 18 FDG PET) allowing the determination of local cerebral metabolic rate of glucose (CMR glc ). The use of 18 FDG in vivo enables the local estimation of total glucose consumption in oxidative and nonoxidative pathways, however without details on further steps in those biochemical pathways, since it does not provide distinction between different labelled metabolic products (chemical specificity). This extension is made possible when using NMR spectroscopy with introduction of stable isotopes, in particular 13 C MRS. Although in recent years metabolic modeling of in vivo 13 C MRS data has been successful in describing the compartmentalized metabolism between neuronal and glial cells, [4] [5] [6] [7] [8] the applicability of highly detailed models is often limited by the intrinsic low sensitivity of the technique, especially in small volumes, as it is the case for mouse brain. Using direct detection of 13 C nuclei, a large number of 13 C resonances are potentially accessible since the wider chemical shift range associated with 13 C spectra compared to indirect detection via 1 H nuclei results in well resolved 13 C peaks, however, at the cost of a more significant chemical shift displacement error. Nevertheless, when taking advantage of the smaller 1 H chemical shift range to perform the localization in the 1 H channel, detection of broadband localized 13 C MRS in vivo spectra in the rat brain after infusion of [1, [6] [7] [8] [9] [10] [11] [12] [13] C 2 ]glucose was shown to be feasible at 9.4 Tesla by using 1 H-localisation and a semi-adiabatic DEPT sequence. 9 Indirect 1 H-[
13 C] MRS detection is an alternative that leads to an increased signal-to-noise ratio (SNR) given the higher gyromagnetic ratio of 1 H, however at the expense of the smaller 1 H chemical shift range, which limits the distinct detection of Glu and Gln C3 and especially C2 7, 10, 11 resonances. More recently, direct 13 C detection and localization in the 1 H channel at ultra-high magnetic fields were combined with a neuro-glial modeling scheme 4 leading to an extended characterization of the fluxes related to energy metabolism and neurotransmission between neurons and glia in the rat brain. 6 The separate detection of Glu and Gln at the position C4 and C3 is the minimal prerequisite to distinctly quantify cell-specific, i.e. astrocytes versus neurons metabolism with minimal assumptions, as was earlier shown for [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C] or [1, [6] [7] [8] [9] [10] [11] [12] [13] C 2 ]glucose infusion protocols. 12 However, the inclusion of Glu and Gln labeling in the position C2 is typically necessary for two-compartment modelling with minimal a priori constraints on glial TCA cycle (V g ) and pyruvate carboxylase rate (V PC ) with infused 13 C-labeled glucose. The addition of other time courses such as aspartate (Asp) labelling generally increases the robustness of the model. 6, 12 The separate measurement of Asp, Glu and Gln at the position C2 remains only feasible through direct detection due to the increased spectral dispersion especially at high magnetic fields. The importance of the inclusion of C3 and C2 Glu/Gln time courses in the modeling arises from the influence of V PC in their progressive labeling: in fact, this chemical reaction leads to labeling accumulation in the position C2 of Glu and Gln while diluting the positions C3 from the incorporation of a 12 C. Besides the sensitivity limitation given by the small volume of the mouse brain compared to larger rodents, the experimental protocol brings additional challenges given the difficulty in performing serial blood sampling during the acquisition. Finally, the reduced size of brain structures entails more pronounced magnetic susceptibility variations that will potentially affect the linewidth and consequently the SNR of the spectra. Nonetheless, extending the application of 13 C MRS to the study of mouse brain and eventually applying metabolic modeling could open the way to the characterization of brain metabolism in different animal models within genetically engineered mice.
To our knowledge, in vivo 13 C MRS in the mouse brain was performed only once using direct detection and infusion of [1, [6] [7] [8] [9] [10] [11] [12] [13] C 2 ]glucose, 13 however without metabolic modelling interpretation, remaining otherwise mainly limited to rat studies. 5, 6, 14, 15 In the present study, we aimed to combine state of the art techniques in 13 C detection in the mouse brain with metabolic modelling of such data for the quantification of neuro-glial fluxes. High-quality 13 C MRS spectra in volumes as small as 112 mL were needed for the measurement of turnover curves of Glu, Gln and Asp with sufficient temporal resolution to be analyzed with a two-compartment model of brain metabolism accounting for distinct neuronal and astrocytic metabolism. 4 Minimal modelling assumptions resulted in a detailed characterization of mouse brain metabolism. For this purpose, a dedicated high sensitivity 13 C/ 1 H surface coil for mice was designed and used in conjunction with a semi-adiabatic polarization transfer sequence to overcome the limitations given by RF field inhomogeneity. CMR glc values derived with PET upon 18 FDG administration in the same brain region were used to provide a cross-validation of the metabolic flux analysis obtained from 13 C MRS metabolic modeling. The feasibility of detailed in vivo dynamic 13 C MRS in mice potentially opens the way to its applicability to a number of transgenic models available or in smaller brain regions, reaching a new standard in spatial resolution with 13 C direct detection.
Materials and methods
All animal experimentation procedures were carried out in compliance with the local ethical guidelines (EXPANIM, Expe´rience sur animaux-SCAV, Service de la consommation et des affaires ve´te´rinaires, Switzerland) and approved by the Veterinary Office of the Canton Vaud. Experimental procedures were reported in compliance with the ARRIVE guidelines.
In vivo 13 C NMR spectroscopy
Six male mice (Swiss NUDE, eight weeks old, 28-30 g, Charles River, L'Arbresle Cedex, France) were used for the 13 C MRS experiments. The mice were housed in filter-top cages, with a 12/12-h light-dark cycle, one mouse per cage. Mice were provided with bedding material, enrichment, and nesting material. They were fasted overnight for 7 h with free access to water before studies. Mice were anesthetized with isoflurane (1-1.5%) for tail vein catheter insertion for substrate administration. Respiration rate ($100 bpm) was monitored continuously during mouse anaesthesia (SA Instruments Inc., NY, USA) and isoflurane level adjusted accordingly. After surgical preparation, mice were transferred in the magnet and placed in a homemade holder that allows fixing the head stereotactically with the help of a bite bar/nose cone and ear rods (Rapid Biomedical, Rimpar, Germany). Body temperature was kept stable (37.0-37.5 C) with the use of a circulating water hose and continuously monitored using a home-built rectal temperature probe. Experiments were performed in a 14.1 Tesla, 26-cm horizontal bore magnet (Varian, Palo Alto, CA/Magnex Scientific, Oxford, UK), using a homebuilt 9-mm( 13 C)/15-mm( 1 H quad) surface coil as receiver and transmitter. The magnet is equipped with actively shielded gradients of (12-cm inner diameter, Magnex Scientific, Oxford, UK) allowing a maximum gradient strength of 400 mT/m in 120 ms. An image acquired with a fast spin-echo sequence was performed in order to position the voxel (TR/TE ¼ 5000/13 ms, FOV ¼ 18 Â 18 mm, slice thickness 1 mm, 4 averages). Magnetic field inhomogeneity was minimized by optimizing first and second-order shims with FAST(EST)MAP 16 (21-29 Hz on localized water peak). A 1 H spectrum was collected in the same voxel as for the dynamic 13 C MRS prior to the adjustment of 13 C MRS parameters and substrate injection, using a short-TE localized SPECIAL sequence 17 (TR/ TE ¼ 4000/2.8 ms) in order to obtain total metabolite concentrations. Direct detection was achieved through a semi-adiabatic DEPT polarization transfer sequence (TR ¼ 2.5 s, interpulse delay of 3.8 ms (optimized for J CH ¼ 130 Hz), 45 for the last 1 H pulse for the simultaneous detection of CH, CH 2 , CH 3 groups) combined with 1 H localization. 9 A small sphere filled with 99% 13 C-enriched formic acid was placed on the top of the coil in order to provide a reference signal both for 13 C offset frequency and B 1 calibration in the 13 C channel, taking into account the changes in coil loading and distance from the measured voxel to the coil. After the calibration, the infusion protocol started with an initial 5-min exponential bolus of 99% enriched [1, [6] [7] [8] [9] [10] [11] [12] [13] C 2 ]glucose, followed by 5 h of continuous infusion of 70% enriched [1, [6] [7] [8] [9] [10] [11] [12] [13] C 2 ]glucose (20% mass per volume solution). The bolus volume per animal weight was 4.01 mL/kg; and the total volume of continuous infusion was 1.99 mL/kg/h. These bolus and continuous infusion rates were established from bench experiments and tail vein blood sampling, where the infusion rate was varied in order to maintain glycemia levels at $ 300 mg/dL. Localized 13 C spectra were acquired from a volume of 112 mL (3.6 Â 6.9 Â 4.5 mm 3 ) covering most of the brain but avoiding lipid contamination from the scalp (Figure 2(c) ). Spectra were acquired continuously over 5 h in blocks of 10.6 min. Shimming was repeated every 32 min in order to keep the linewidth constant.
Spectra quantification of 1 H and
13
C spectra was performed using LCModel. 18 Normalization procedure of spectra for absolute quantification of 13 C metabolite concentrations is described as Supplementary Information. Normalization for RF efficiency on resonances at different frequency offsets as well as for the different efficiency of the DEPT transfer for CH and CH 2 groups was achieved applying a correction factor derived from a natural abundance spectrum acquired on a phantom filled with non-labeled compounds (Glu, Gln, Asp) and scanned under identical experimental conditions. O (4 mg/ml), NaCl (7.5 mg/ml), and Na 2 S 2 O 3.5 H 2 O (1.3-1.9 mg/ml).
FDG positron emission tomography
Six healthy male NUDE mice (33.4-35.4 g) were used for the PET experiments. Mice were anesthetized for tail vein catheter insertion (25G home-made catheter). Initial values of glycemia were obtained at the same time, prior to administration of 18 FDG. List-mode acquisitions were obtained with a single field of view centered on the body midsection, allowing the inclusion of the brain and inferior vena cava, and initiated with i.v. injection of 18 FDG (1.6 AE 0.3 MBq/g body weight; mean AE SD; volume of injectate 50-400 mL) through the tail vein catheter within the first 10 s of the PET scan, followed by 100-150 mL of saline chase solution. Imaging was performed using an avalanche photodiode micro-PET scanner (LabPET4, GammaMedica, Sherbrook Canada). Mice were maintained under 1% isoflurane anaesthesia in oxygen delivered at 0.9 L/min using a face mask with constant monitoring of temperature and breathing rate. An energy window of 250-650 keV and a coincidence timing window of 22.2 ns were used for the detection of photons at 511 keV resulting from annihilated electron-positron pairs. For image reconstruction, a built-in iterative maximum likelihood expectation maximum-based image (MLEM) reconstruction algorithm was used in a cylindrical volume of 46 mm in diameter and 7 cm in length. Voxel size measured 0.5 Â 0.5 Â 1.18 mm 3 , giving a typical resolution of <1.2 mm at the center of the FOV.
For temporal histogramming, the following time frames (F) were used: 24 F of 5 s duration; 6 F of 30 s duration; 5 F of 2 min duration; and 7 F of 5 min duration. All post-processing of images was performed using PMOD 2.95 software (PMOD Technologies Ltd, Switzerland).
The image-derived input function (IDIF) was determined from the time activity curves (TAC) of 18 FDG in the blood at the level of the inferior vena cava. 19 Briefly, the volume of interest (VOI) drawn for the input function consisted in four adjacent regions of interest (1 mm 2 surface and 1.18 mm thickness) in axial slices in correspondence of the vena cava. Their location was established based on visual inspection of the maximum intensity projection image in the coronal plane where the flow of 18 FDG was observed during the bolus. The brain tissue TACs (tTACs) were selected from mid-brain and were of the same volume and shape as the region scanned during 13 C MRS ( Figure 5 ). The measured radioactivity was corrected for the 18 F radioactive decay (relative to the start of the acquisition).
Metabolic modeling of 13 C MRS data 13 C MRS dynamic data were modelled following a neuro-glial compartmentalized scheme, as previously shown. 4 Two-compartment scheme for glucose metabolism and label scrambling from [1, [6] [7] [8] [9] [10] [11] [12] [13] C 2 ]glucose into the different carbon positions of the measured amino acids are summarized in Figure 1 . 
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NAA 6 (a) (b) Figure 1 . (a) Two-compartmental model of neuro-glial metabolism in the brain used to describe 13 C label transfer upon [1, [6] [7] [8] [9] [10] [11] [12] [13] C 2 ]glucose infusion in the present study. Glucose is rapidly taken up by brain tissue from the blood stream after passing through the blood-brain barrier. Glycolysis converts it into pyruvate (Pyr) which is not detectable in vivo due to its small pool size. Given the rapid exchange between Pyr and lactate (Lac) as compared to the TCA cycle flux, they are considered as an indistinguishable pool that is in turn diluted by V Ldil (inflow from blood-borne lactate) and loses 13 C label through V out (outflow towards blood). In both compartment, Pyr is converted into acetyl-CoA (AcCoA), which is entering the TCA cycle. The glial compartment is characterized by conversion of Pyr into oxaloacetate (OAA) through pyruvate carboxylase (V PC ) and by glial specific substrates V dil g . Conversion of AcCoA in 2-oxoglutarate (OG) leads to glutamate (Glu) synthesis in both compartments through the transmitochondrial flux V x (V x þ V PC in the glial compartment). After a synaptic neurotransmitter release, Glu is rapidly taken up from the synaptic cleft by glial
The two-compartment scheme considers glucose as the main brain energy substrate, where it is rapidly transported from the blood stream through the blood-brain barrier (BBB) into the cerebral tissue compartment. There, glycolysis metabolizes glucose into pyruvate (Pyr) which is, in turn, in rapid exchange with the lactate (Lac) pool through lactate dehydrogenase (LDH) thereby converting labeling in C1 and C6 positions of glucose into C3 of Pyr and lactate. 13 C labeling is diluted at this node due to exchange with blood lactate (V Ldil ). Moreover, the model accounts for a small lactate efflux for contribution to nonoxidative pathways (V out ). Label from Pyr flows into neuronal and glial TCA cycles: PC activity is essentially localized in the glial compartment 20 contributing to the replenishment of TCA cycle intermediates, while influx of glial-specific substrates is considered through a dilution flux at the level of Acetyl-CoA (AcCoA) in the glial compartment 6 (V dil g ). Label at the level of AcCoA flows through the TCA cycle to 2OG that is in exchange across the mitochondrial membrane with Glu in both compartments. In the further part of the TCA cycle, 13 C can flow alternatively from OG to oxaloacetate (OAA) for further cycling. The glial TCA cycle flux V TCA g is determined from mass-balance considerations on the OG pool as the sum of the conversion rate between OG and OAA (V g ) and V PC , while neuronal TCA cycle (V TCA n ) corresponds to Pyr dehydrogenase rate in neurons. In the glial compartment, the forward conversion between OG and Glu occurs at the rate V x þ V PC , rather than V x solely, due to mass-balance considerations on the TCA intermediate pools. Glu synthetized in neurons is retained in presynaptic vesicles, released in the synaptic cleft during the glutamatergic neurotransmission process and promptly taken-up by glial cells after postsynaptic excitation to regulate extracellular Glu homeostasis. Gln synthetase (V GS ) synthetizes Gln from Glu specifically in the glial compartment. 21 Again, mass-balance considerations on glial Glu and Gln lead to the equivalence V GS ¼ V NT þ V PC and the correspondence V efflux ¼ V PC at metabolic steady-state. Finally, Gln participates indirectly to neurotransmission by being released in the extracellular space and subsequently taken up by neurons, serving as precursor for Glu synthesis and replenishment of neurotransmitter vesicles. The transmitochondrial flux V x acts as exchange flux between OAA and Asp pools as well as between OG and Glu in neurons in the malate-Asp shuttle.
The set of differential equations that characterize the 13 C labelling dynamics in the presented twocompartment model was derived from the reaction pathways in the neuronal and the glial compartments as described above at metabolic steady-state (see Supplementary Information). The input function was generated as a step function with 70% glucose fractional enrichment (FE). 13 C time courses obtained from spectral quantification of individual animals were first averaged over all the subjects. The values of the metabolic fluxes characterizing the two-compartment model (V tca n , V g , V x , V PC , V NT , V dil g , and V out ) were determined in a twostep process. First, the set of differential equations was at first iteratively solved with a Runge-Kutta method and solutions were fitted to the measured 13 C FE turnover curves by adjusting the metabolic flux values (regression parameters) using a Levenberg-Marquardt algorithm for non-linear regression. FE curves were weighted in the regression cost function by the inverse of their variance, based on their respective noise level, to avoid bias in the parameters regression. In the second step, the precision of the estimated fluxes was determined by Monte Carlo (MC) simulation of the 13 C FE time courses (N ¼ 300). 22 Briefly, after the estimation of the metabolic fluxes by the weighted regression method, the fluxes were employed to generate a collection of noise-free 13 C FE turnover curves, also used to evaluate the noise level in each turnover curve by subtraction: N sets of artificial 13 C turnover curves were generated by adding N realizations of Gaussian noise with corresponding noise level to the noise-free model curves. A probability distribution for each metabolic flux is then obtained by fitting the N sets of artificial turnover curves. The standard deviation (SD) of each distribution determines the uncertainty on the estimated fluxes.
Metabolic modeling of 18 FDG kinetics in PET experiments
The time activity curves of 18 FDG acquired from the blood and the brain over a 50 min duration were processed using Patlak graphical analysis, 23 allowing an estimation of CMR glc from the slope of the resulting linear segment for each animal. The model predicts that FDG radioactivity concentration (in kBq/ml) at a given time t, and C Ã t ðtÞ the total tissue radioactivity concentration. The slope of the linear fitting curve is equal to K* from which CMR glc is estimated as
where C P is the plasma glucose concentration, and LC is the lumped constant, fixed to 0.625 for mice. 24, 25 Plasma glucose is assumed to remain constant throughout the PET scan, which is supported by the fact that 18 FDG is injected in pM concentrations and it is presumed not to perturb glucose homeostasis.
Biological systems can be studied with a Patlak analysis under the essential condition of irreversible trapping of the tracer under study, meaning that once 18 FDG is metabolized in the cell (i.e. it undergoes phosphorylation), de-phosphorylation is not possible (k* 4 ¼ 0). This assumption can be considered valid for a scanning duration shorter than 27 min in the mouse brain. [25] [26] [27] On the other hand, the time point t* defines the time delay that is necessary to reach equilibrium in FDG transport that will hence become unidirectional. In the IF, t* is the time point characterized by a nearly zero-slope in the curve after the bolus peak. Passed that time, FDG radioactivity concentration in blood will continue to decrease due to a combined effect of FDG uptake by major organs and muscles, as well as kidneys and bladder (frequently referred to as product loss). Specific t* of 5 min was chosen to allow sufficient time for reaching equilibrium in the exchange between plasma and tissue compartment.
The complete equation for the Patlak regression line is
where V d accounts for the non-zero intercept in the y axis, which represents the initial volume of distribution.
Results
In vivo 13 C MR spectra were obtained dynamically from mouse brain in six animals for up to 5 h during infusion of [1, [6] [7] [8] [9] [10] [11] [12] [13] C 2 ]glucose, in a volume of interest of 112 mL (Figure 2(c) ). 13 C MRS spectra acquired during the first 2.5 h with a temporal resolution of 10.6 min showed excellent sensitivity and spectral resolution in the selected VOI, reaching an SNR of eight after only 160 min (Figure 2(b) ). GlcC6, LacC3 and GluC4 peaks rose in magnitude from the first 5 min, reflecting a prompt increase of blood glucose 13 C level. Other amino acid resonances were increasingly visible during the first hour (Figure 2(a) ). Spectral resolution was such that Glu and Gln peaks were well separated in all carbon positions C4, C3, and C2.
Steady-state spectra acquired during 92 min after 3.5 h of [1,6-13 C 2 ]glucose infusion, showed outstanding SNR (>20) and spectral resolution (FWHM ¼ 15 Hz) allowing detection of 17 distinct resonances (Figure 3(a) ) that account for a wide range of brain metabolites involved in glucose glycolytic catabolism and oxidation, synthesis of aminoacids and neurotransmitters. GlcC6 was the first peak to appear followed by LacC3 (Figure 2(a) ), labeled from PyrC3 as AlaC3 (Figure 1(b) ). Although cerebral alanine (Ala) has a relatively small pool size compared to Lac, AlaC3 became visible during the first hour (Figure 2(a) ) and appeared clearly in steady-state spectra (Figure 3(a) ). GABA is the primary neurotransmitter involved in inhibitory signaling and is directly synthetized by GABAergic neurons from Glu. Therefore, label in positions C4, C3, and C2 of Glu is transferred to GABAC2, C3, and C4, respectively, resulting in the appearance of fairly prominent peaks given its relatively large pool size in the striatum (3.1 AE 0.2 mmol/g, mean AE SD, as measured from the pre-infusion 1 H MRS scan). Asp is labeled from OAA through the V x exchange flux (Figure 1(b) 
GlcC6
GluC2 GlnC2 positions were clearly detected in steady-state spectra (Figure 3(a) ). High spectral resolution allowed distinct detection of multiplets at the position C3 and C4 of Glu and Gln (Figure 3(b) ). This feature allowed the calculation of the FE of GluC3 at steady-state and therefore the rescaling of 13 C concentrations in the spectra (see Supplementary Information) .
The fairly tight SD of the FE curves ( Figure 4 ) demonstrated high reproducibility between animals. Maximal FE in GluC4 and GlnC4 reached 50% and 37%, respectively, at steady-state, while positions C3 were at 40% and 32%, respectively, indicating that the latter were likely diluted by PC activity. The lower FE of carbons C4 compared to glucose (70%) is the direct consequence of the dilution flux at the level of the lactate pool (V out ) which will equally influence Glu and Gln, while incorporation of glial-specific substrates (V dil g ) results mostly in the dilution of Gln curves. Moreover, PC introduces additional labeling in the positions C2 of Glu and Gln: this was observable from a higher FE of 44% and 41% at steady-state, respectively, compared to the C3 carbons. Experimental curves of Glu C4, C3, and C2, Gln C4, C3, and C2 and AspC3 were fitted by the two-compartmental model for brain metabolism (Figure 1(a) ). The following metabolic fluxes were determined (Table 1) (0.38 AE 0.02 mmol/g/min) was determined as (V TCA n þ V TCA g þ V PC )/2. To determine the total CMR glc independently from 13 C MRS experiments, we used 18 FDG PET. Specifically, CMR glc rates in mice brain were determined by metabolic modeling of 18 FDG uptake with Patlak graphical analysis, dynamically detected in a group of six mice. Data were quantified in a voxel corresponding to the one used for 13 C MRS located in the mid brain ( Figure 5(b) ). Examination of linearity in Patlak plots between 5 and 27 min from the injection led to quantification of CMR glc for each animal. R 2 values (0.92-0.99) were examined to evaluate the goodness of the fit in the selected time frame. Averaging of CMR glc over the entire group resulted in a global value of 0.4 AE 0.1 mmol/g/min (mean AE SD).
Discussion
In the present study, direct detection 13 C MRS spectra were applied from the mouse brain to quantify compartmentalized metabolism between neurons and glial (Figure 1(a) ). The black solid line represents the best fit as obtained by least square fitting. Dashed lines represent SD range determined from MC simulation for each experimental curve. Note: Metabolic fluxes (expressed in mmol/g/min) determined from metabolic modeling of experimental data, based on the scheme shown in Figure 1 . Errors express SD derived from MC simulation with a set of N ¼ 300 artificial set of curves for Glu, Gln, and Asp. CMR glc(ox) is calculated as (V TCA n þ V TCA g þ V PC )/2. V TCA n : rate of neuronal TCA cycle; V g : rate of glial TCA cycle; V PC : pyruvate carboxylase rate; V x : transmitochondrial flux rate; V NT : apparent rate of glutamatergic neurotransmission.
cells. Monte Carlo simulation showed that metabolic rates were precisely determined, including the fluxes specific to the glial compartment (maximal error of 19% on V g ).
The high spectral quality attained was achieved by integrating state of the art 13 C direct detection 9 and shimming techniques 16 at ultra-high field (14.1 Tesla), combined with the use of an optimized homemade 1 H-13 C surface coil. The excellent sensitivity achieved in an exceptionally small volume (i.e. 112 mL, Figure 2 (c)) allowed separate detection of three aliphatic carbons of Glu and Gln (C4, C3, and C2) up to 13 C- 13 C multiplet resolution (Figure 3(b) ) as well as the measurement of a wide range of brain metabolites linked to glucose metabolism in the brain, as Asp, GABA, NAA, Ala, and Lac. All peaks were separately resolved (Figure 3(a) ) with the only exception of GABAC4 and NAAC3 that have very similar chemical shifts (respectively 40.2 and 40.3 ppm), thus appearing inevitably overlapped, even at this field strength.
Direct detection technique further allowed separate detection of Glu and Gln in the position C2 that are commonly overlapped in indirect 1 H-[ 13 C] MRS detection. 7, 10, 11, 28, 29 V PC enables de novo synthesis of carbon skeletons entering the TCA cycle specifically in the glial compartment and introduces additional labeling at the level of Gln C2, while diluting the C3 position. Thus, the distinct detection of GlnC2 and GluC2 time courses is of great importance when aiming for robustness in metabolic modeling of neuro-glial interactions with minimal assumptions. 6, 12 The high temporal resolution of the measurements, i.e. 10.6 min (Figure 2) , allowed for mathematical modeling of neuro-glial metabolism, based on labelling of Glu and Gln at the carbon positions C4, C3, and C2 and Asp at the position C3. The measurements were assessed to be highly reproducible between individual animals, as seen from the relatively narrow SD intervals of the group-averaged 13 C turnover curves. This was ascribed to the implementation of the standardized infusion protocol and reproducible experimental conditions, despite the inaccessibility of plasma glucose level during infusion.
Metabolic fluxes
The present study represents to our knowledge the first attempt of mathematical modeling of cerebral metabolism in mice based on in vivo 13 C-labeling experiments with direct 13 C detection. Previous studies [4] [5] [6] 14, 15 have applied similar techniques to the human and rat brain gaining important insights on cerebral metabolic compartmentation, whereas cerebral metabolism in mice has only been described by ex vivo measurements 30 or by 13 C indirect detection 11 subsequently analysed by simplified one-compartment model of brain metabolism. While indirect detection gave access to real-time information on the pool size during infusion, 11 including the input function, 11 direct detection reduces the peak overlap and increases the number of dynamically detectable metabolites carbon positions. In the present model, 1 H MRS spectra enabled the determination of metabolites pool size in vivo to derive FE values for each metabolite included in the metabolic modeling, by assuming constant pool size over the experiment.
The obtained neuronal and glial TCA cycle fluxes were comparable with values from published data in human and rat brain in vivo as well in the mouse brain ex vivo (Table 2) . Neuronal TCA cycle rate in the awake human brain at rest averages to 0.7 AE 0.09 mmol/g/min 2 , while it tends to be lower in rats and mice ( Table 2) .
The transmitochondrial exchange flux V x was comparable to V TCA n , similar to previous studies. 3, 11, 6, 15, 31 This implies that the malate-Asp shuttle is a major mechanism of label transfer across the mitochondrial membrane, as discussed previously. 3 The metabolic fluxes determined in this study represent an average over the examined VOI and are thus expected to be mostly influenced by metabolic exchanges in the central part of the brain, mainly the striatum. V NT can vary considerably through different brain regions and is typically higher in regions dominated by excitatory synapses (i.e. cortex) characterized by higher rates of glucose oxidation. 30 Conversely, the striatum is known for the higher level of GABA (and therefore likely higher role of GABAergic neurotransmission) when compared to cortex, hippocampus and cerebellum 30, 32 and the lower rate of excitatory neurotransmission compared to other regions in the mouse brain. 30 Therefore, the rate V NT found in this study reflected this pattern and was consistent with previously published values in rats in vivo. 8, 6 Glial TCA cycle rate and PC rate were in agreement with previously published values in rats (Tables 1 and 2) , with V PC being one order of magnitude smaller than V g .
Beyond these observations, metabolic rates could be dependent on the specific strain used in the experiment and possibly from the use of anaesthetics. 33, 34 However, a deeper understanding of these aspects is far from being attained given the limited number of studies available on the topic.
In our study, the levels of brain Lac (4.3 AE 0.8 mmol/ g), enabled the measurement of Lac enrichment turnover, as early as 5 min after the start of the infusion.
1 H MRS studies of metabolite concentrations in the mouse brain indicated a higher cerebral Lac concentration in this species 32 compared to rats, 35 especially in the striatum, where levels as high as 5 mmol/g were reported in C57BL/6 mice. 32 Given this relatively low concentration in rats (usually below 2 mmol/g in the rat striatum 35 ), Lac peaks are often barely detectable in 13 C MRS studies under physiological conditions upon infusion of labeled glucose, 9, 6 whereas a complete time course was registered in the mouse brain by 13 C indirect detection. 11 Therefore, in such experiments, which give access to dynamic information of the Lac pool size, the 13 C Lac signal could in principle be used as input function of the mathematical modeling, as previously demonstrated 11 . However, in 13 C direct detection studies, it is generally not recommended to determine dynamically the Lac FE curve by assuming a constant pool size for Lac, since volatile anaesthetics 36, 37 and nearly hyperglycemic plasma concentrations of glucose could induce fluctuations of total Lac concentration over the course of the experiment and would similarly influence Ala. Increasing pool size of the measured metabolites does not represent an obstacle to the measurement of metabolic fluxes, as non-steady-state regime can be taken into account in the modeling when realtime information on metabolite pool size is accessible. 8, 11 CMR glc determined by 18 FDG PET experiments
Total cerebral glucose consumption was evaluated by simplified 18 FDG kinetic modeling: the linear regression method applied in Patlak plots for each animal enabled the determination of the CMR glc in the VOI matched to that of 13 C MRS, under the fundamental assumption of irreversible FDG-6P kinetics. Patlak graphical analysis 23 is advantageous in evaluating the net glucose uptake by the brain given the simplicity of the linear regression method when separate information on the transport of FDG to the cellular compartment and its phosphorylation are not necessary. The temporal range examined was fixed between 5 and 27 min, similar to previously published procedures in mice. 25, 27 The first few minutes are in fact influenced by equilibration between plasma and tissue FDG, while the last time point included was set to be before 30 min in order to minimize the influence of k* 4 (dephosphorylation of FDG-6P). FDG-6P reaches typically a plateau 20 min after FDG bolus injection, resulting in a non-negligible effect of dephosphorylation mostly between 30 min and the end of the experiments. [25] [26] [27] The effect of a nonnegligible dephosphatase activity was discernible from the decline of the Patlak curve in the four time points corresponding to 30 to 50 min ( Figure 5(a) ).
Linear relationships were established in the aforementioned time frames as justified from R 2 values for each linear fit (0.92-0.99). Reported values and their variability for CMR glc in the brain were comparable to other FDG PET studies in mice under isoflurane. 26, 27, 38, 39 The value of CMR glc(ox) derived from the amino acids turnover using 13 C MRS (0.38 AE 0.02 mmol/g/ min) is comparable to CMR glc quantified from PET experiments. However, a slightly higher glucose metabolism measured by 18 FDG PET is consistent, given that glucose can be in part metabolized by glycolysis to lactate and to a smaller extent to glycogen ( 18 FDG PET measures CMR glc(total) ).
For the present study, we conclude that cerebral brain metabolism can be assessed in vivo in mice with direct 13 C MR spectroscopy at 14.1 Tesla. Given the high spectral quality obtained in the chosen volume of detection (112 mL), we expect that sufficient SNR could be obtained in the near future in volumes as small as 60 mL for the detection of C4, C3, and C2 resonances of Glu and Gln, giving access to the detection of regional glucose metabolism in astrocytes and neurons. The FE time courses available from those labeled metabolites allowed us for the first time to obtain a complete twocompartmental description of brain energy metabolism in mice.
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